History of antimicrobial drug discovery: Major classes and health impact

Biochemical Pharmacology

Volumn 133, Issue , 2017, Pages 4-19

  Aminov, Rustam ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antimicrobial drug discovery; History

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANSAMYCIN DERIVATIVE; ANTIINFECTIVE AGENT; ARSPHENAMINE; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; GLYCOPEPTIDE; LINCOSAMIDE; MACROLIDE; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; HISTORY; HUMAN; INFECTION; MORBIDITY; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BACTERIAL INFECTIONS; CLASSIFICATION; DRUG DEVELOPMENT; PROCEDURES; TRENDS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG DISCOVERY; HUMANS;

EID: 84992195331     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.10.001     Document Type: Review

References (250)

1. [1] Abraham, E.P., Chain, E., An enzyme from bacteria able to destroy penicillin. Nature, 146, 1940, 837, 10.1038/146837a0.
2. [2] Acar, J., Casewell, M., Freeman, J., Friis, C., Goossens, H., Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making. Clin. Microbiol. Infect. 6:9 (2000), 477–482, 10.1046/j.1469-0691.2000.00128.x.
3. [3] Ahmed, A., Daneshtalab, M., Nonclassical biological activities of quinolone derivatives. J. Pharm. Pharm. Sci. 15:1 (2012), 52–72, 10.18433/J3302N.
4. [4] Allington, D.R., Rivey, M., Quinupristin/dalfopristin: a therapeutic review. Clin. Ther. 23:1 (2001), 24–44, 10.1016/S0149-2918(01)80028-X.
5. [5] Aminov, R.I., Mackie, R.I., Evolution and ecology of antibiotic resistance genes. FEMS Microbiol. Lett. 271 (2007), 147–161, 10.1111/j.1574-6968.2007.00757.x.
6. [6] Aminov, R.I., The role of antibiotics and antibiotic resistance in nature. Environ. Microbiol. 11 (2009), 2970–2988, 10.1111/j.1462-2920.2009.01972.x.
7. [7] Aminov, R.I., A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol., 1, 2010, 134, 10.3389/fmicb.2010.00134.
8. [8] Aminov, R.I., Horizontal gene exchange in environmental microbiota. Front. Microbiol., 2, 2011, 158, 10.3389/fmicb.2011.00158.
9. [9] Aminov, R.I., The extent and regulation of lateral gene transfer in natural microbial ecosystems. Francino, M.P., (eds.) Horizontal Gene Transfer in Microorganisms, 2012, Horizon Scientific Press, Norwich NR9 3DB, UK 978-1-908230-10-2 Chapter 6.
10. [10] Aminov, R.I., Biotic acts of antibiotics. Front. Microbiol., 4, 2013, 241, 10.3389/fmicb.2013.00241.
11. [11] Aminov, R.I., Evolution in action: dissemination of tet(X) into pathogenic microbiota. Front. Microbiol., 4, 2013, 192, 10.3389/fmicb.2013.00192.
12. [12] Amsden, G.W., Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18:Suppl. 1 (2001), S11–S15, 10.1016/S0924-8579(01)00410-1.
13. [13] Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., Jarlier, V., A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:5707 (2005), 223–227, 10.1126/science.1106753.
14. [14] Arias, C.A., Murray, B.E., The rise of the Enterococcus: beyond vancomycin resistance. Nat. Rev. Microbiol. 10:4 (2012), 266–278, 10.1038/nrmicro2761.
15. [15] Armelagos, G.J., Disease in ancient Nubia. Science 163 (1969), 225–258, 10.1126/science.163.3864.255.
16. [16] Armstrong, G.L., Conn, L.A., Pinner, R.W., Trends in infectious disease mortality in the United States during the 20th century. JAMA 281:1 (1999), 61–66, 10.1001/jama.281.1.61.
17. [17] Arthur, M., Reynolds, P.E., Depardieu, F., Evers, S., Dutka-Malen, S., Quintiliani, R. Jr, Courvalin, P., Mechanisms of glycopeptide resistance in enterococci. J. Infect. 32:1 (1996), 11–16, 10.1016/S0163-4453(96)80003-X.
18. [18] Bacitracin. 2010. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=529.
19. [19] Bager, F., Madsen, M., Christensen, J., Aarestrup, F.M., Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev. Vet. Med. 31:1–2 (1997), 95–112, 10.1016/S0167-5877(96)01119-1.
20. [20] Bala, S., Khanna, R., Dadhwal, M., Prabagaran, S.R., Shivaji, S., Cullum, J., Lal, R., Reclassification of Amycolatopsis mediterranei DSM 46095 as Amycolatopsis rifamycinica sp. nov. Int. J. Syst. Evol. Microbiol. 54:4 (2004), 1145–1149, 10.1099/ijs.0.02901-0.
21. [21] Baldry, P., The Battle Against Bacteria: A Fresh Look. 1976, Cambridge University Press, New York, NY ISBN-13: 978-0521212687, ISBN-10: 0521212685.
22. [22] Balerna, M., Keller-Schierlein, W., Martius, C., Wolf, H., Zähner, H., Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K. Arch. Mikrobiol. 65:4 (1969), 303–317.
23. [23] Baltz, R.H., Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13:2 (2009), 144–151, 10.1016/j.cbpa.2009.02.031.
24. [24] Bardone, M.R., Paternoster, M., Coronelli, C., Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization. J. Antibiot. (Tokyo) 31:3 (1978), 170–177.
25. [25] Barnhart, C.E., Robertson, J.C., Miller, H.W., Virginiamycin, a new antibiotic for growing swine. J. Anim. Sci., 19, 1960, 9.
26. [26] Barnhill, A.E., Brewer, M.T., Carlson, S.A., Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob. Agents Chemother. 56:8 (2012), 4046–4051, 10.1128/AAC.00678-12.
27. [27] Bartmann, K., Iwainsky, H., Kleeberg, H.H., Mison, P., Offe, H.A., Otten, H., Tettenborn, D., Trnka, L., Antituberculosis Drugs. Bartman, K., (eds.), 2013, Springer Science Business Media, 566 ISBN 3642728731, 9783642728730.
28. [28] Bassett, E.J., Keith, M.S., Armelagos, G.J., Martin, D.L., Villanueva, A.R., Tetracycline-labelled human bone from ancient Sudanese Nubia (A.D. 350). Science 209 (1980), 1532–1534.
29. [29] Batalha, P.N., de Souza, M.C., Peña-Cabrera, E., Cruz, D.C., da Costa Santos Boechat, F., Quinolones in the search for new anticancer agents. Curr. Pharm. Des., 2016 Jul 15 [Epub ahead of print].
30. [30] Batchelor, F.R., Doyle, F.P., Nayler, J.H.C., Rolinson, G.N., Synthesis of penicillin: 6-aminopenicillanic acid in penicillin fermentations. Nature 183 (1959), 257–258, 10.1038/183257b0.
31. [31] Bax, R., Green, S., Antibiotics: the changing regulatory and pharmaceutical industry paradigm. J. Antimicrob. Chemother. 70:5 (2015), 1281–1284, 10.1093/jac/dku572.
32. [32] Bedin, M., Gaben, A.M., Saucier, C.C., Mester, J., Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int. J. Cancer 109:5 (2004), 643–652, 10.1002/ijc.20010.
33. [33] Bernareggi, A., Borghi, A., Borgonovi, M., Cavenaghi, L., Ferrari, P., Vékey, K., Zanol, M., Zerilli, L.F., Teicoplanin metabolism in humans. Antimicrob. Agents Chemother. 36:8 (1992), 1744–1749.
34. [34] Bertrand, D., Bertrand, S., Neveu, E., Fernandes, P., Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54:12 (2010), 599–5402, 10.1128/AAC.00840-10.
35. [35] Binda, E., Marinelli, F., Marcone, G.L., Old and new glycopeptide antibiotics: action and resistance. Antibiotics (Basel) 3:4 (2014), 572–594, 10.3390/antibiotics3040572.
36. [36] Birkenmeyer, R.D., Kagan, F., Lincomycin. XI. Synthesis and structure of clindamycin, a potent antibacterial agent. J. Med. Chem. 13:4 (1970), 616–619, 10.1021/jm00298a007.
37. [37] Bischoff, K.M., Zhang, Y., Rich, J.O., Fate of virginiamycin through the fuel ethanol production process. World J. Microbiol. Biotechnol., 32(5), 2016, 76, 10.1007/s11274-016-2026-3.
38. [38] Boneca, I.G., Chiosis, G., Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opin. Ther. Targets 7:3 (2003), 311–328, 10.1517/14728222.7.3.311.
39. [39] Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B., Bartlett, J., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (2009), 1–12, 10.1086/595011.
40. [40] Bollenbach, T., Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr. Opin. Microbiol. 27 (2015), 1–9, 10.1016/j.mib.2015.05.008.
41. [41] Brickner, S.J., Oxazolidinone antibacterial agents. Curr. Pharm. Des. 2:2 (1996), 175–194.
42. [42] Brockmann, H., Henkel, W., Pikromycin, ein neues Antibiotikum aus Actinomycetes. Naturwissenschaften 37 (1950), 138–139.
43. [43] Brockmann, H., Henkel, W., Pikromycin, ein bitter schmeckendes Antibioticum aus Actinomyceten. Antibiotica aus Actinomyceten 84 (1951), 184–288, 10.1002/cber.19510840306.
44. [44] Brook, I., Antimicrobials therapy of anaerobic infections. J. Chemother. 28:3 (2016), 143–150, 10.1179/1973947815Y.0000000068.
45. [45] Brunton, L.L., Lazo, J.S., Parker, K., Protein synthesis inhibitors and miscellaneous antibacterial agents. Chapter 46. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed., 2005, McGraw-Hill, New York, 2021 ISBN 0-07-142280-3.
46. [46] Bucci, R., Galli, P., Vincenzo Tiberio: a misunderstood researcher. Ital. J. Public Health 8:4 (2011), 404–406, 10.2427/5688.
47. [47] Burke, E.T., The arseno-therapy of syphilis; stovarsol, and tryparsamide. Br. J. Vener. Dis. 1:4 (1925), 321–338, 10.1136/sti.1.4.321.
48. [48] Burkhart, B.M., Gassman, R.M., Langs, D.A., Pangborn, W.A., Duax, W.L., Pletnev, V., Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers 51:2 (1999), 129–144 DOI: 10.1002/(SICI)1097-0282(1999)51:2<129::AID-BIP3>3.0.CO;2-Y.
49. [49] Bush, K., Bradford, P.A., β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb. Perspect. Med., 2016, a025247, 10.1101/cshperspect.a025247.
50. [50] Castanon, J.I., History of the use of antibiotic as growth promoters in European poultry feeds. Poult. Sci. 86 (2007), 2466–2471, 10.3382/ps.2007-00249.
51. [51] CDC, Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www. cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
52. [52] Cha, J.Y., Ishiwata, A., Mobashery, S., A novel β-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin. J. Biol. Chem. 279 (2004), 14917–14921, 10.1074/jbc.M400666200.
53. [53] Chain, E., Florey, H.W., Gardner, A.D., Heatley, N.G., Jennings, M.A., Orr-Ewing, J., Sanders, A.G., THE CLASSIC: penicillin as a chemotherapeutic agent. 1940. Clin. Orthop. Relat. Res. 439 (2005), 23–26.
54. [54] Chang, S., Sievert, D.M., Hageman, J.C., Boulton, M.L., Tenover, F.C., Downes, F.P., Shah, S., Rudrik, J.T., Pupp, G.R., Brown, W.J., Cardo, D., Fridkin, S.K., Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:14 (2003), 1342–1347, 10.1056/NEJMoa025025.
55. [55] Charney, J., Fisher, W.P., Curran, C., Machlowitz, R.A., Tytell, A.A., Streptogramin, a new antibiotic. Antibiot. Chemother. (Northfield) 3:12 (1953), 1283–1286.
56. [56] Chatham House Report, 2015. Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales. Edited by C. Clift, U. Gopinathan, C. Morel, K. Outterson, J.-A. Røttingen, A. So. Available at: https://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf.
57. [57] Chopra, I., Roberts, M., Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:2 (2001), 232–260, 10.1128/MMBR.65.2.232-260.2001.
58. [58] Cocito, C., Antibiotics of the virginiamycin family, inhibitors which contain synergistic components. Microbiol. Rev. 43:2 (1979), 145–192.
59. [59] Collignon, P.J., Vancomycin-resistant enterococci and use of avoparcin in animal feed: is there a link?. Med. J. Aust. 171:3 (1999), 144–146.
60. [60] Corey, E.J., Drug Discovery Practices, Processes, and Perspectives. 2013, John Wiley & Sons, Hoboken, N.J. p. 406. ISBN 9781118354469.
61. [61] Collaborators, Global Burden of Disease Study 2013. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:9995 (2013), 743–800, 10.1016/S0140-6736(15)60692-4.
62. [62] Cook, M., Molto, E., Anderson, C., Fluorochrome labelling in Roman period skeletons from Dakhleh Oasis, Egypt. Am. J. Phys. Anthropol. 80 (1989), 137–143, 10.1002/ajpa.1330800202.
63. [63] Crowley, B.M., Boger, D.L., Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 128:9 (2006), 2885–2892, 10.1021/ja0572912.
64. [64] Delgado, G. Jr., Neuhauser, M.M., Bearden, D.T., Danziger, L.H., Quinupristin-dalfopristin: an overview. Pharmacotherapy 20 (2000), 1469–1485.
65. [65] Denning, D.W., Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:6 (2002), 889–891, 10.1093/jac/dkf045.
66. [66] Desjardins, C.A., Cohen, K.A., Munsamy, V., Abeel, T., Maharaj, K., Walker, B.J., Shea, T.P., Almeida, D.V., Manson, A.L., Salazar, A., Padayatchi, N., O'Donnell, M.R., Mlisana, K.P., Wortman, J., Birren, B.W., Grosset, J., Earl, A.M., Pym, A.S., Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat. Genet. 48:5 (2016), 544–551, 10.1038/ng.3548.
67. [67] Di Giambattista, M., Chinali, G., Cocito, C., The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes. J. Antimicrob. Chemother. 4 (1989), 485–507, 10.1093/jac/24.4.485.
68. [68] Dinos, G.P., Athanassopoulos, C.M., Missiri, D.A., Giannopoulou, P.C., Vlachogiannis, I.A., Papadopoulos, G.E., Papaioannou, D., Kalpaxis, D.L., Chloramphenicol derivatives as antibacterial and anticancer agents: historic problems and current solutions. Antibiotics (Basel), 5(2), 2016 pii: E20. DOI: 10.3390/antibiotics5020020.
69. [69] Domagk, G., Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Deutsch. Med. Wschr., 61, 1935, 250, 10.1055/s-0028-1129486.
70. [70] Dubern, J.F., Diggle, S.P., Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas aeruginosa and other bacterial species. Mol. BioSyst. 4 (2008), 882–888, 10.1039/b803796p.
71. [71] Duggar, B.M., Aureomycin: a product of the continuing search for new antibiotics. Ann. N. Y. Acad. Sci. 51 (1948), 177–181, 10.1111/j.1749-6632.1948.tb27262.x.
72. [72] Ehrlich, P., Hata, S., Die Experimentelle Chemotherapie der Spirilosen. 1910, Julius Springer, Berlin.
73. [73] Eliakim-Raz, N., Lador, A., Leibovici-Weissman, Y., Elbaz, M., Paul, M., Leibovici, L., Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 70:4 (2015), 979–996, 10.1093/jac/dku530.
74. [74] Eliopoulos, G.M., Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36 (2003), 473–481, 10.1086/367662.
75. [75] Enne, V.I., Bennett, P.M., Livermore, D.M., Hall, L.M., Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. J. Antimicrob. Chemother. 53 (2004), 958–963, 10.1093/jac/dkh217.
76. [76] EPC, Ban on Antibiotics as Growth Promoters in Animal Feed Enters into Effect, European Commission – IP/05/1687, 2005. Available at: http://europa.eu/rapid/press-release_IP-05-1687_en.htm.
77. [77] Eschenauer, G., Depestel, D.D., Carver, P.L., Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 3:1 (2007), 71–97, 10.2147/tcrm.2007.3.1.71.
78. [78] Falagas, M.E., Kasiakou, S.K., Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:9 (2005), 1333–1341.
79. [79] Falagas, M.E., Grammatikos, A.P., Michalopoulos, A., Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev. Anti-infective Ther. 6:5 (2008), 593–600, 10.1586/14787210.6.5.593.
80. [80] FDA, Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. Department of Health and Human Services, 2009. Available at: www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM231851.pdf.
81. [81] FDA, FDA News Release, 2012. Available at: ( http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm).
82. [82] FDA, FDA approves Sivextro to treat skin infections, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm402174.htm.
83. [83] FDA, FDA Announces Pending Withdrawal of Approval of Nitarsone, 2015. Available at: www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm440668.htm.
84. [84] FDA, Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals, 2015. Available at: https://docs.google.com/viewer?url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FForIndustry%2FUserFees%2FAnimalDrugUserFeeActADUFA%2FUCM440584.pdf.
85. [85] FDA, Fluoroquinolone Antibacterial Drugs: Drug Safety Communication – FDA Advises Restricting Use for Certain Uncomplicated Infections, 2016. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500665.htm.
86. [86] Fleming, A., On antibacterial action of culture of penicillium, with special reference to their use in isolation of B. influenzae. Br. J. Exp. Pathol. 10 (1929), 226–236.
87. [87] Floss, H.G., Yu, T.W., Rifamycin-mode of action, resistance, and biosynthesis. Chem. Rev. 105:2 (2005), 621–632, 10.1021/cr030112j.
88. [88] French, G., Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51:Suppl. 2 (2003), ii45–ii53, 10.1093/jac/dkg253.
89. [89] Friedman, L., Alder, J.D., Silverman, J.A., Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:6 (2006), 2137–2145, 10.1128/AAC.00039-06.
90. [90] Gardete, S., Tomasz, A., Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 124:7 (2014), 2836–2840, 10.1172/JCI68834.
91. [91] Garrido-Mesa, N., Zarzuelo, A., Gálvez, J., Minocycline: far beyond an antibiotic. Br. J. Pharmacol. 169 (2013), 337–352, 10.1111/bph.12139.
92. [92] Gause, G.F., Brazhnikova, M.G., Gramicidin S and its use in the Treatment of Infected Wounds. Nature, 154(3918), 1944, 703, 10.1038/154703a0.
93. [93] Good, J.T. Jr, Rollins, D.R., Martin, R.J., Macrolides in the treatment of asthma. Curr. Opin. Pulm. Med. 18 (2012), 76–84, 10.1097/MCP.0b013e32834daff8.
94. [94] Goossens, H., Ferech, M., Vander Stichele, R., Elseviers M, ESAC Project Group, Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 (2005), 579–587, 10.1016/S0140-6736(05)17907-0.
95. [95] Greenwood, D., Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. 2008, Oxford University Press, 464 ISBN 9780199534845.
96. [96] Groves, R.D., Hetzel, A.M., Vital Statistics Rates in the United States, 1940-1960. 1968, National Center for Health Statistics, Washington, DC, 1968 (PHS publication no. 1677).
97. [97] Grüneberg, R.N., Hryniewicz, W., Clinical relevance of a European collaborative study on comparative susceptibility of Gram-positive clinical isolates to teicoplanin and vancomycin. Int. J. Antimicrob. Agents 10:4 (1998), 271–277.
98. [98] Hallen, H., Luo, H., Scott-Craig, J.S., Walton, J.D., A gene family encoding the major toxins of lethal Amanita mushrooms. Proc. Natl. Acad. Sci. U.S.A. 104:48 (2007), 19097–19101, 10.1073/pnas.0707340104.
99. [99] Hamilton-Miller, J.M., Chemistry and biology of the polyene macrolide antibiotics. Bacteriol. Rev. 37:2 (1973), 166–196.
100. [100] Hamilton-Miller, J., From foreign pharmacopoeias: ‘new’ antibiotics from old?. J. Antimicrob. Chemother. 27:6 (1991), 702–705, 10.1093/jac/27.6.702.
101. [101] Hancock, R.E., Sahl, H.G., Antimicrobial and host-defence peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006), 1551–1557, 10.1038/nbt1267.
102. [102] Harms, J.M., Schluenzen, F., Fucini, P., Bartels, H., Yonath, A.E., Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol., 2, 2004, 4, 10.1186/1741-7007-2-4.
103. [103] Hays, E.E., Wells, I.C., Katzman, P.A., Cain, C.K., Jacobs, F.A., Thayer, S.A., Doisy, E.A., Gaby, W.L., Roberts, E.C., Muir, R.D., Carroll, C.J., Jones, L.R., Wade, N.J., Antibiotic substances produced by Pseudomonas aeruginosa. J. Biol. Chem. 159 (1945), 725–750.
104. [104] Heeb, S., Fletcher, M.P., Chhabra, S.R., Diggle, S.P., Williams, P., Cámara, M., Quinolones: from antibiotics to autoinducers. FEMS Microbiol. Rev. 35:2 (2011), 247–274, 10.1111/j.1574-6976.2010.00247.x.
105. [105] Hegde, S.S., Vetting, M.W., Roderick, S.L., Mitchenall, L.A., Maxwell, A., Takiff, H.E., Blanchard, J.S., A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308 (2005), 1480–1483.
106. [106] Hiasa, H., Shea, M.E., DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex. J. Biol. Chem. 275 (2000), 34780–34786, 10.1074/jbc.M001608200.
107. [107] Hicks, L.A., Taylor, T.H. Jr., Hunkler, R.J., U.S. outpatient antibiotic prescribing, 2010. N. Engl. J. Med. 368:15 (2013), 1461–1462, 10.1056/NEJMc1212055.
108. [108] Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, F.C., Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:1 (1997), 135–136, 10.1093/jac/40.1.135.
109. [109] Hochstein, F.A., Stephens, C.R., Conover, L.H., Regna, P.P., Pasternack, R., Gordon, P.N., Pilgrim, F.J., Brunings, K.J., Woodward, R.B., The structure of terramycin. J. Am. Chem. Soc. 75:22 (1953), 5455–5475, 10.1021/ja01118a001.
110. [110] Hummert, J., Van Gerven, D., Tetracycline-labeled human bone from a medieval population in Nubia's Batn El Hajar (550–1450 A.D.). Hum. Biol. 54:2 (1982), 355–363.
111. [111] Hughes, C.C., Fenical, W., Antibacterials from the sea. Chemistry 16:42 (2010), 12512–12525, 10.1002/chem.201001279.
112. [112] Ištuk, Z.M., Cikoš, A., Gembarovski, D., Lazarevski, G., Dilović, I., Matković-Čalogović, D., Kragol, G., Novel 9a,11-bridged azalides: One-pot synthesis of N′-substituted 2-imino-1,3-oxazolidines condensed to an azalide aglycone. Bioorg. Med. Chem. 19 (2011), 556–566, 10.1016/j.bmc.2010.10.061.
113. [113] IUPAC, Compendium of Chemical Terminology, 2nd ed. (the “Gold Book”). Compiled by A.D. McNaught, A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). XML on-line corrected version: http://goldbook.iupac.org (2006-) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. ISBN 0-9678550-9-8. doi: 10.1351/goldbook.
114. [114] James, R.C., Pierce, J.G., Okano, A., Xie, J., Boger, D.L., Redesign of glycopeptide antibiotics: back to the future. ACS Chem. Biol. 7:5 (2012), 797–804, 10.1021/cb300007j.
115. [115] Jenke-Kodama, H., Sandmann, A., Müller, R., Dittmann, E., Evolutionary implications of bacterial polyketide synthases. Mol. Biol. Evol. 22:10 (2005), 2027–2039, 10.1093/molbev/msi193.
116. [116] Jones, R.N., Kohno, S., Ono, Y., Ross, J.E., Yanagihara, K., ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 g-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64:2 (2009), 191–201, 10.1016/j.diagmicrobio.2009.03.001.
117. [117] Kazimierczak, K.A., Scott, K.P., Kelly, D., Aminov, R.I., Tetracycline resistome of the organic pig gut. Appl. Environ. Microbiol. 75 (2009), 1717–1722, 10.1128/AEM.02206-08.
118. [118] Khosla, C., Gokhale, R.S., Jacobsen, J.R., Cane, D.E., Tolerance and specificity of polyketide synthases. Annu. Rev. Biochem. 68 (1999), 219–253, 10.1146/annurev.biochem.68.1.219.
119. [119] King, D.T., Sobhanifar, S., Strynadka, N.C., One ring to rule them all: current trends in combating bacterial resistance to the β-lactams. Protein Sci. 25:4 (2016), 787–803, 10.1002/pro.2889.
120. [120] Kingston, W., Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J. Hist. Med. Allied Sci. 59:3 (2004), 441–462, 10.1093/jhmas/jrh091.
121. [121] Kittendorf, J.D., Sherman, D.H., The methymycin/pikromycin biosynthetic pathway: a model for metabolic diversity in natural product. Bioorg. Med. Chem. 17 (2009), 2137–2146, 10.1016/j.bmc.2008.10.082.
122. [122] Klinker, K.P., Borgert, S.J., Beyond vancomycin: the tail of the lipoglycopeptides. Clin. Ther. 37:12 (2015), 2619–2636, 10.1016/j.clinthera.2015.11.007.
123. [123] Klopper, M., Warren, R.M., Hayes, C., Gey van Pittius, N.C., Streicher, E.M., Müller, B., Sirgel, F.A., Chabula-Nxiweni, M., Hoosain, E., Coetzee, G., David van Helden, P., Victor, T.C., Trollip, A.P., Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg. Infect. Dis. 9:3 (2013), 449–455, 10.3201//EID1903.120246.
124. [124] Koehn, F.E., Carter, G.T., The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4:3 (2005), 206–220, 10.1038/nrd1657.
125. [125] Kopp, F., Marahiel, M.A., Macrocyclization strategies in polyketide and nonribosomal peptide biosynthesis. Nat. Prod. Rep. 24:4 (2007), 735–749, 10.1039/b613652b.
126. [126] Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D., Andries, K., Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3:6 (2007), 323–324, 10.1038/nchembio884.
127. [127] Krause, K.M., Serio, A.W., Kane, T.R., Connolly, L.E., Aminoglycosides: an overview. Cold Spring Harb. Perspect. Med., 6(6), 2016, a027029, 10.1101/cshperspect.a027029.
128. [128] Krishnasamy, V., Otte, J., Silbergeld, E., Antimicrobial use in Chinese swine and broiler poultry production. Antimicrob. Resist. Infect. Control, 4, 2015, 17, 10.1186/s13756-015-0050-y.
129. [129] Kudoh, S., Uetake, T., Hagiwara, K., Hirayama, M., Hus, L.H., Kimura, H., Sugiyama, Y., Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25 (1987), 632–642.
130. [130] Kumarasamy, K.K., Toleman, M.A., Walsh, T.R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C.G., Irfan, S., Krishnan, P., Kumar, A.V., Maharjan, S., Mushtaq, S., Noorie, T., Paterson, D.L., Pearson, A., Perry, C., Pike, R., Rao, B., Ray, U., Sarma, J.B., Sharma, M., Sheridan, E., Thirunarayan, M.A., Turton, J., Upadhyay, S., Warner, M., Welfare, W., Livermore, D.M., Woodford, N., Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10 (2010), 597–602, 10.1016/S1473-3099(10)70143-2.
131. [131] Kushner, B., Allen, P.D., Crane, B.T., Frequency and demographics of gentamicin use. Otol. Neurotol. 37:2 (2016), 190–195, 10.1097/MAO.0000000000000937.
132. [132] Landers, T.F., Cohen, B., Wittum, T.E., Larson, E.L., A review of antibiotic use in food animals: perspective, policy, and potential. Public Health Rep. 127:1 (2012), 4–22.
133. [133] Lawrence, P.A., Rank injustice. Nature 415:6874 (2002), 835–836, 10.1038/415835a.
134. [134] Lechevalier, M.P., Prauser, H., Labeda, D.P., Ruan, J.S., Two new genera of nocardioform actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov. Int. J. Syst. Evol. Microbiol. 36:1 (1986), 29–37, 10.1099/00207713-36-1-29.
135. [135] Leclercq, R., Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:4 (2002), 482–492, 10.1086/324626.
136. [136] Lee, G.C., Reveles, K.R., Attridge, R.T., Lawson, K.A., Mansi, I.A., Lewis, J.S. 2nd, Frei, C.R., Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med., 12, 2014, 96, 10.1186/1741-7015-12-96.
137. [137] Levine, D., Vancomycin: a history. Clin. Infect. Dis. 42 (2006), S5–S12, 10.1086/491709.
138. [138] Llano-Sotelo, B., Dunkle, J., Klepacki, D., Zhang, W., Fernandes, P., Cate, J.H., Mankin, A.S., Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob. Agents Chemother. 54:12 (2010), 4961–4970, 10.1128/AAC.00860-10.
139. [139] Lindsay, R., Zhou, H., Cosman, F., Nieves, J., Dempster, D., Double and quadruple tetracycline labelling of bone: impact of the label itself. J. Bone Miner. Res. 28:1 (2013), 222–223, 10.1002/jbmr.1818.
140. [140] Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., Yu, L.F., Gu, D., Ren, H., Chen, X., Lv, L., He, D., Zhou, H., Liang, Z., Liu, J.H., Shen, J., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16:2 (2016), 161–168, 10.1016/S1473-3099(15)00424-7.
141. [141] Livermore, D.M., Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51:Suppl. 2 (2003), ii9–ii16, 10.1093/jac/dkg249.
142. [142] Lloyd, N.C., Morgan, H.W., Nicholson, B.K., Ronimus, R.S., The composition of Ehrlich's salvarsan: resolution of a century-old debate. Angew. Chem. Int. Ed. Engl. 44 (2005), 941–944, 10.1002/anie.200461471.
143. [143] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S.Y., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M., Barker-Collo, S., Bartels, D.H., Bell, M.L., Benjamin, E.J., Bennett, D., Bhalla, K., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Blyth, F., Bolliger, I., Boufous, S., Bucello, C., Burch, M., Burney, P., Carapetis, J., Chen, H., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahodwala, N., De Leo, D., Degenhardt, L., Delossantos, A., Denenberg, J., Des Jarlais, D.C., Dharmaratne, S.D., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Erwin, P.J., Espindola, P., Ezzati, M., Feigin, V., Flaxman, A.D., Forouzanfar, M.H., Fowkes, F.G., Franklin, R., Fransen, M., Freeman, M.K., Gabriel, S.E., Gakidou, E., Gaspari, F., Gillum, R.F., Gonzalez-Medina, D., Halasa, Y.A., Haring, D., Harrison, J.E., Havmoeller, R., Hay, R.J., Hoen, B., Hotez, P.J., Hoy, D., Jacobsen, K.H., James, S.L., Jasrasaria, R., Jayaraman, S., Johns, N., Karthikeyan, G., Kassebaum, N., Keren, A., Khoo, J.P., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Lipnick, M., Lipshultz, S.E., Ohno, S.L., Mabweijano, J., MacIntyre, M.F., Mallinger, L., March, L., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGrath, J., Mensah, G.A., Merriman, T.R., Michaud, C., Miller, M., Miller, T.R., Mock, C., Mocumbi, A.O., Mokdad, A.A., Moran, A., Mulholland, K., Nair, M.N., Naldi, L., Narayan, K.M., Nasseri, K., Norman, P., O'Donnell, M., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Pahari, B., Pandian, J.D., Rivero, A.P., Padilla, R.P., Perez-Ruiz, F., Perico, N., Phillips, D., Pierce, K., Pope, C.A. 3rd, Porrini, E., Pourmalek, F., Raju, M., Ranganathan, D., Rehm, J.T., Rein, D.B., Remuzzi, G., Rivara, F.P., Roberts, T., De León, F.R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Salomon, J.A., Sampson, U., Sanman, E., Schwebel, D.C., Segui-Gomez, M., Shepard, D.S., Singh, D., Singleton, J., Sliwa, K., Smith, E., Steer, A., Taylor, J.A., Thomas, B., Tleyjeh, I.M., Towbin, J.A., Truelsen, T., Undurraga, E.A., Venketasubramanian, N., Vijayakumar, L., Vos, T., Wagner, G.R., Wang, M., Wang, W., Watt, K., Weinstock, M.A., Weintraub, R., Wilkinson, J.D., Woolf, A.D., Wulf, S., Yeh, P.H., Yip, P., Zabetian, A., Zheng, Z.J., Lopez, A.D., Murray, C.J., AlMazroa, M.A., Memish, Z.A., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2095–2128, 10.1016/S0140-6736(12)61728-0.
144. [144] Lutz, L., Pereira, D.C., Paiva, R.M., Zavascki, A.P., Barth, A.L., Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol., 12, 2012, 196, 10.1186/1471-2180-12-196.
145. [145] MacLeod, A.J., Ross, H.B., Ozere, R.L., Digout, Geo., van Rooyen, C.E., Lincomycin: a new antibiotic active against staphylococci and other gram-positive cocci. Can. Med. Assoc. J. 91:20 (1964), 1056–1060.
146. [146] MacNeil, I.A., Tiong, C.L., Minor, C., August, P.R., Grossman, T.H., Loiacono, K.A., Lynch, B.A., Phillips, T., Narula, S., Sundaramoorthi, R., Tyler, A., Aldredge, T., Long, H., Gilman, M., Holt, D., Osburne, M.S., Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 3 (2001), 301–308.
147. [147] Makovitzki, A., Avrahami, D., Shai, Y., Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 15997–16002, 10.1073/pnas.0606129103.
148. [148] Mahoney, J., Arnold, R., Harris, A., Penicillin treatment of early syphilis: a preliminary report. Am. J. Public Health Nations Health 33:12 (1943), 1387–1391.
149. [149] Margalith, P., Beretta, G., Rifomycin. XI. Taxonomic study on Streptomyces mediterranei nov. sp. Mycopathol. Mycol. Appl. 13:4 (1960), 321–330, 10.1007/BF02089930.
150. [150] Marsot, A., Guilhaumou, R., Riff, C., Blin, O., Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin. Pharmacokinet., 2016 Jun 21. [Epub ahead of print].
151. [151] Martinez-Sandoval, F., Ericsson, C.D., Jiang, Z.D., Okhuysen, P.C., Romero, J.H., Hernandez, N., Forbes, W.P., Shaw, A., Bortey, E., DuPont, H.L., Prevention of travelers’ diarrhea with rifaximin in US travelers to Mexico. J. Travel Med. 17:2 (2010), 111–117, 10.1111/j.1708-8305.2009.00385.x.
152. [152] C.V. Maxwell, D.S. Buchanan, W.G. Luce, D. McLaren, R. Vend, Direct Comparisons of Antibiotics for Growing-Finishing Swine. Animal Science Research Report, Oklahoma Agricultural Experiment Station, 235-240, 1981. Available at: http://beefextension.com/research_reports/research_56_94/rr82/rr82_55.pdf.
153. [153] McGuire, J.M., Bunch, R.L., Anderson, R.C., Boaz, H.E., Flynn, E.H., Powell, H.M., Smith, J.W., Ilotycin, a new antibiotic. Antibiot. Chemother. (Northfield) 2:6 (1952), 281–283.
154. [154] Migliori, G.B., De Iaco, G., Besozzi, G., Centis, R., Cirillo, D.M., First tuberculosis cases in Italy resistant to all tested drugs. Euro. Surveill., 12(20), 2007 pii=3194. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3194.
155. [155] Moellering, R.C., Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138:2 (2003), 135–142, 10.7326/0003-4819-138-2-200301210-00015.
156. [156] Morris, M.I., Villmann, M., Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health Syst. Pharm. 63:18 (2006), 1693–1703, 10.2146/ajhp050464.p1.
157. [157] Mukhtar, T.A., Koteva, K.P., Wright, G.D., Chimeric streptogramin-tyrocidine antibiotics that overcome streptogramin resistance. Chem. Biol. 12:2 (2005), 229–235, 10.1016/j.chembiol.2004.12.009.
158. [158] Murphy, S., Pinney, R.J., Teicoplanin or vancomycin in the treatment of gram-positive infections?. J. Clin. Pharm. Ther. 20:1 (1995), 5–11.
159. [159] Mutak, S., Azalides from azithromycin to new azalide derivatives. J. Antibiot. (Tokyo) 60 (2007), 85–122, 10.1038/ja.2007.10.
160. [160] Nagai, H., Shishido, H., Yoneda, R., Yamaguchi, E., Tamura, A., Kurashima, A., Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58 (1991), 145–149.
161. [161] Napier, B.A., Burd, E.M., Satola, S.W., Cagle, S.M., Ray, S.M., McGann, P., Pohl, J., Lesho, E.P., Weiss, D.S., Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio, 4(3), 2013, e00021 13, 10.1128/mBio.00021-13.
162. [162] Nelson, M.L., Dinardo, A., Hochberg, J., Armelagos, G.J., Brief communication: mass spectroscopic characterization of tetracycline in the skeletal remains of an ancient population from Sudanese Nubia 350–550 CE. Am. J. Phys. Anthropol. 143 (2010), 151–154, 10.1002/ajpa.21340.
163. [163] Nelson, M.L., Levy, S.B., The history of the tetracyclines. Ann. N. Y. Acad. Sci. 1241 (2011), 17–32, 10.1111/j.1749-6632.2011.06354.x.
164. [164] Norrby, S.R., Nord, C.E., Finch, R., European Society of Clinical Microbiology and Infectious Diseases, Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 5 (2005), 115–119, 10.1016/S1473-3099(05)01283-1.
165. [165] Okano, A., Nakayama, A., Schammel, A.W., Boger, D.L., Total synthesis of [Ψ[C([dbnd]NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 136:39 (2014), 13522–13525, 10.1021/ja507009a.
166. 4]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide antibiotics. J. Am. Chem. Soc. 137:10 (2015), 3693–3704, 10.1021/jacs.5b01008.
167. [167] Oliynyk, M., Samborskyy, M., Lester, J.B., Mironenko, T., Scott, N., Dickens, S., Haydock, S.F., Leadlay, P.F., Complete genome sequence of the erythromycin-producing bacterium Saccharopolyspora erythraea NRRL23338. Nat. Biotechnol. 25 (2007), 447–453, 10.1038/nbt1297.
168. [168] J. O'Neill (Chair), The Review on Antimicrobial Resistance, 2014. Available at: http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
169. [169] Ortwine, J.K., Kaye, K.S., Li, J., Pogue, J.M., Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy 35:1 (2015), 11–16, 10.1002/phar.1484.
170. [170] Outterson, K., Rex, J.H., Jinks, T., Jackson, P., Hallinan, J., Karp, S., Hung, D.T., Franceschi, F., Merkeley, T., Houchens, C., Dixon, D.M., Kurilla, M.G., Aurigemma, R., Larsen, J., Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat. Rev. Drug Discov. 15:9 (2016), 589–590, 10.1038/nrd.2016.155.
171. [171] J. Parascandola, The history of antibiotics: a symposium. American Institute of the History of Pharmacy No. 5, 1980. ISBN 0-931292-08-5.
172. [172] Parenti, F., Beretta, G., Berti, M., Arioli, V., Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. J. Antibiot. (Tokyo) 31:4 (1978), 276–283.
173. [173] Parenti, F., Schito, G.C., Courvalin, P., Teicoplanin chemistry and microbiology. J. Chemother. 12:Suppl. 5 (2000), 5–14.
174. [174] Pfizer, 2010. Available at: https://docs.google.com/viewer?url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2010%2F021130s022lbl.pdf.
175. [175] Plikaytis, B.B., Marden, J.L., Crawford, J.T., Woodley, C.L., Butler, W.R., Shinnick, T.M., Multiplex PCR assay specific for the multidrug-resistant strain W of Mycobacterium tuberculosis. J. Clin. Microbiol. 32 (1994), 1542–1546.
176. [176] Pogliano, J., Pogliano, N., Silverman, J.A., Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J. Bacteriol. 194:17 (2012), 4494–4504, 10.1128/JB.00011-12.
177. [177] Ponziani, F.R., Pecere, S., Lopetuso, L., Scaldaferri, F., Cammarota, G., Gasbarrini, A., Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opin. Drug Saf. 15:7 (2016), 983–991, 10.1080/14740338.2016.1186639.
178. [178] Pootoolal, J., Neu, J., Wright, G.D., Glycopeptide antibiotic resistance. Annu. Rev. Pharmacol. Toxicol. 42 (2002), 381–408, 10.1146/annurev.pharmtox.42.091601.142813.
179. [179] Prenner, E.J., Lewis, R.N., Neuman, K.C., Gruner, S.M., Kondejewski, L.H., Hodges, R.S., McElhaney, R.N., Nonlamellar phases induced by the interaction of gramicidin S with lipid bilayers. A possible relationship to membrane-disrupting activity. Biochemistry 36:25 (1997), 7906–7916, 10.1021/bi962785k.
180. [180] Prosser, G.A., de Carvalho, L.P., Kinetic mechanism and inhibition of Mycobacterium tuberculosis d-alanine: D-alanine ligase by the antibiotic d-cycloserine. FEBS J. 280:4 (2013), 1150–1166, 10.1111/febs.12108.
181. [181] Rahman, H., Austin, B., Mitchell, W.J., Morris, P.C., Jamieson, D.J., Adams, D.R., Spragg, A.M., Schweizer, M., Novel anti-infective compounds from marine bacteria. Mar. Drugs 8 (2010), 498–518, 10.3390/md8030498.
182. [182] Ramaswamy, S., Musser, J.M., Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:1 (1998), 3–29, 10.1054/tuld.1998.0002.
183. [183] Rao, G.G., Ly, N.S., Haas, C.E., Garonzik, S., Forrest, A., Bulitta, J.B., Kelchlin, P.A., Holden, P.N., Nation, R.L., Li, J., Tsuji, B.T., New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob. Agents Chemother. 58:3 (2014), 1381–1388, 10.1128/AAC.00327-13.
184. [184] Redin, G.S., Antibacterial activity in mice of minocycline, a new tetracycline. Antimicrob. Agents Chemother. 6 (1966), 371–376.
185. [185] Rice, L.B., Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197 (2009), 1079–1081, 10.1086/533452.
186. [186] Rinehart, Kenneth L. Jr., Knoll, Waltraut M., Kakinuma, Katsumi, Antosz, Frederick J., Paul, Iain C., Wang, Andrew H.J., Reusser, Fritz, Li, L.H., Krueger, William C., Chemistry and biochemistry of the streptovaricins. XII. Atropisomeric streptovaricins. J. Am. Chem. Soc. 97:1 (1975), 196–198, 10.1021/ja00834a039.
187. [187] Roberts, K.D., Sulaiman, R.M., Rybak, M.J., Dalbavancin and oritavancin: an innovative approach to the treatment of gram-positive infections. Pharmacotherapy 35:10 (2015), 935–948, 10.1002/phar.
188. [188] Robertson, G.T., Bonventre, E.J., Doyle, T.B., In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (2008), 2313–2323.
189. [189] Rollo, I.M., Williamson, J., Plackett, R.L., Acquired resistance to penicillin and to neoarsphenamine in Spirochaeta recurrentis. Br. J. Pharmacol. Chemother. 7 (1952), 33–41.
190. [190] Rose, W., Rybak, M., Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26:8 (2006), 1099–1110, 10.1592/phco.26.8.1099.
191. [191] Roskoski, R., Gevers, W., Kleinkauf, H., Lipmann, F., Tyrocidine biosynthesis by three complementary fractions from Bacillus brevis (ATCC 8185). Biochemistry 9:25 (1970), 4839–4845, 10.1021/bi00827a002.
192. [192] Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D.S., Toan, S.V., Bruijn, L.I., Su, Z.Z., Gupta, P., Fisher, P.B., Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005), 73–77.
193. [193] Rothstein, D.M., van Duzer, J., Sternlicht, A., Gilman, S.C., Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections. Arch. Pharm. (Weinheim) 340:10 (2007), 517–529.
194. [194] Rybak, M.J., The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin. Microbiol. Infect. 12:Suppl. 1 (2006), 24–32.
195. [195] Sartor, R.B., Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment. Pharmacol. Ther. 43:Suppl. 1 (2016), 27–36, 10.1111/apt.13436.
196. [196] Scheinfeld, N., Telithromycin: a brief review of a new ketolide antibiotic. J. Drug Dermatol. 3 (2004), 409–413.
197. [197] Schwarz, S., Kehrenberg, C., Doublet, B., Cloeckaert, A., Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol. Rev. 28:5 (2004), 519–542.
198. [198] Seema, J., Lleras-Muney, A., Smith, K.V., Modern medicine and the twentieth century decline in mortality: evidence on the impact of sulfa drugs. Am. Econ. J.: Appl. Econ. 2:2 (2010), 118–146, 10.1257/app.2.2.118.
199. [199] Seemungal, T.A.R., Wilkinson, T.M.A., Hurst, J.R., Perera, W.R., Sapsford, R.J., Wedzicha, J.A., Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178 (2008), 1139–1147, 10.1164/rccm.200801-145OC.
200. [200] Sensi, P., History of the development of rifampin. Rev. Infect. Dis. 5:Suppl. 3 (1983), S402–S406, 10.1093/clinids/5.Supplement_3.S402.
201. [201] Sepkowitz, K.A., Rafalli, J., Riley, L., Kiehn, T.E., Armstrong, D., Tuberculosis in the AIDS era. Clin. Microbiol. Rev. 8:2 (1995), 180–199.
202. [202] Shapiro, D.J., Hicks, L.A., Pavia, A.T., Hersh, A.L., Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J. Antimicrob. Chemother. 69:1 (2014), 234–240, 10.1093/jac/dkt301.
203. [203] Shigeri, Y., Seal, R.P., Shimamoto, K., Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Rev. 45 (2004), 250–265, 10.1016/j.brainresrev.2004.04.004.
204. [204] Shinabarger, D., Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs 8:8 (1999), 1195–1202, 10.1517/13543784.8.8.1195.
205. [205] Shnayerson, M., Plotkin, M., The Killers Within: The Deadly Rise of Drug-Resistant Bacteria. 2003, Back Bay Books ISBN 978-0-316-73566-7.
206. [206] Slee, A.M., Wuonola, M.A., McRipley, R.J., Zajac, I., Zawada, M.J., Bartholomew, P.T., Gregory, W.A., Forbes, M., Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 31:11 (1987), 1791–1797, 10.1128/AAC.31.11.1791.
207. [207] Soriano, A., Miró, O., Mensa, J., Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353:21 (2005), 2305–2306, 10.1056/NEJM200511243532123.
208. [208] Spanogiannopoulos, P., Waglechner, N., Koteva, K., Wright, G.D., A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria. Proc. Natl. Acad. Sci. U.S.A. 111:19 (2014), 7102–7107, 10.1073/pnas.1402358111.
209. [209] Speer, B.S., Bedzyk, L., Salyers, A.A., Evidence that a novel tetracycline resistance gene found on two Bacteroides transposons encodes an NADP-requiring oxidoreductase. J. Bacteriol. 173:1 (1991), 176–183.
210. [210] Spencer, C.M., Bryson, H.M., Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections. Pharmacoeconomics 7:4 (1995), 357–374.
211. [211] Stammer, C.H., Wilson, A.N., Holly, F.W., Folkers, K., Synthesis of D-4-amino-3-isoxazolidinone. J. Am. Chem. Soc. 77 (1955), 2346–2347, 10.1021/ja01613a107.
212. [212] Steenbergen, J.N., Alder, J., Thorne, G.M., Tally, F.P., Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:3 (2005), 283–288, 10.1093/jac/dkh546.
213. [213] Kaufmann, S.H.E., Paul Ehrlich: founder of chemotherapy. Nat. Rev. Drug Discov., 7, 2008, 373, 10.1038/nrd2582.
214. [214] Steverding, D., The development of drugs for treatment of sleeping sickness: a historical review. Parasit. Vectors, 3(1), 2010, 15, 10.1186/1756-3305-3-15.
215. [215] Storm, D.R., Rosenthal, K.S., Swanson, P.E., Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46 (1977), 723–763, 10.1146/annurev.bi.46.070177.003451.
216. [216] Sugimoto, T., Tanikawa, T., Suzuki, K., Yamasaki, Y., Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as ‘11a-azalides’. Bioorg. Med. Chem. 20 (2012), 5787–5801, 10.1016/j.bmc.2012.08.007.
217. [217] Talbot, G.H., Bradley, J., Edwards, J.E. Jr, Gilbert, D., Scheld, M., Bartlett, J.G., Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42 (2006), 657–668, 10.1086/499819.
218. [218] Tally, F.P., DeBruin, M.F., Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:4 (2000), 523–526, 10.1093/jac/46.4.523.
219. [219] Tenson, T., Lovmar, M., Ehrenberg, M., The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol. 330:5 (2003), 1005–1014, 10.1016/S0022-2836(03)00662-4.
220. [220] Thiemann, J.E., Zucco, G., Pelizza, G., A proposal for the transfer of Streptomyces mediterranei Margalith and Beretta 1960 to the genus Nocardia as Nocardia mediterranea (Margalith and Beretta) comb. nov. Arch. Mikrobiol. 67:2 (1969), 147–155.
221. [221] Thomas, C., Stevenson, M., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J. Antimicrob. Chemother. 51:6 (2003), 1339–1350, 10.1093/jac/dkg254.
222. [222] Tran, J.H., Jacoby, G.A., Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 5638–5642, 10.1073/pnas.082092899.
223. [223] Tran, J.H., Jacoby, G.A., Hooper, D.C., Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 49 (2005), 118–125, 10.1128/AAC.49.1.118-125.2005.
224. [224] Tréfouël, J., Tréfouël, T., Nitti, F., Bovet, D., Activité du p-aminophénylsulfamide sur l'infection streptococcique expérimentale de la souris et du lapin. C. R. Soc. Biol., 120, 1935, 756.
225. [225] Tupin, A., Gualtieri, M., Roquet-Banères, F., Morichaud, Z., Brodolin, K., Leonetti, J.P., Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. Int. J. Antimicrob. Agents 35:6 (2010), 519–523, 10.1016/j.ijantimicag.2009.12.017.
226. [226] Udwadia, Z.F., Amale, R.A., Ajbani, K.K., Rodriguez, C., Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54 (2012), 579–581, 10.1093/cid/cir889.
227. [227] Urry, D.W., The gramicidin A transmembrane channel: a proposed pi(L, D) helix. Proc. Natl. Acad. Sci. U.S.A. 68:3 (1971), 672–676.
228. [228] Van Bambeke, F., Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7:8 (2006), 740–749.
229. [229] Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., Laxminarayan, R., Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14:8 (2014), 742–750, 10.1016/S1473-3099(14)70780-7.
230. [230] Van Boeckel, T.P., Brower, C., Gilbert, M., Grenfell, B.T., Levin, S.A., Robinson, T.P., Teillant, A., Laxminarayan, R., Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. U.S.A. 112:18 (2015), 5649–5654, 10.1073/pnas.1503141112.
231. [231] Velayati, A.A., Masjedi, M.R., Farnia, P., Tabarsi, P., Ghanavi, J., Ziazarifi, A.H., Hoffner, S.E., Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis of totally drug-resistant strain in Iran. Chest 136 (2009), 420–425, 10.1378/chest.08-2427.
232. [232] Velayati, A.A., Farnia, P., Masjedi, M.R., The totally drug resistant tuberculosis (TDR-TB). Int. J. Clin. Exp. Med. 6:4 (2013), 307–309.
233. [233] Wainwright, M., Streptomycin: discovery and resultant controversy. Hist. Philos. Life Sci. 13:1 (1991), 97–124.
234. [234] Wainwright, M.A., Response to William Kingston, “Streptomycin, Schatz versus Waksman, and the balance of credit for discovery”. J. Hist. Med. Allied Sci. 60:2 (2005), 218–220, 10.1093/jhmas/jri024.
235. [235] Waksman, S., The Conquest of Tuberculosis. 1964, University of California Press, Berkeley, CA, 241.
236. [236] Wehrli, W., Staehelin, M., Actions of the rifamycins. Bacteriol. Rev. 35:3 (1971), 290–309.
237. [237] Weisblum, B., Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39 (1995), 577–585, 10.1128/AAC.39.3.577.
238. [238] Wentland, M.P., In memoriam: George Y. Lesher, Ph.D. Hooper, D.C., Wolfson, J.S., (eds.) Quinolone Antimicrobial Agents, 2nd ed., 1993, American Society for Microbiology, Washington DC, XIII–XIV.
239. [239] Wood, M.J., The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 37:2 (1996), 209–222.
240. [240] Wright, G.D., The origins of antibiotic resistance. Handb. Exp. Pharmacol. 211 (2012), 13–30, 10.1007/978-3-642-28951-4_2.
241. [241] Wright, L.T., Schreiber, H., The clinical value of aureomycin: a review of current literature and some unpublished data. J. Natl Med. Assoc. 41:5 (1949), 195–201.
242. [242] Wright, A.J., The penicillins. Mayo Clin. Proc. 74:3 (1999), 290–307, 10.4065/74.3.290.
243. [243] Xie, J., Pierce, J.G., James, R.C., Okano, A., Boger, D.L., A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J. Am. Chem. Soc. 133:35 (2011), 13946–13949, 10.1021/ja207142h.
244. [244] Xie, J., Okano, A., Pierce, J.G., James, R.C., Stamm, S., Crane, C.M., Boger, D.L., Total synthesis of [Ψ[C([dbnd]S)NH]Tpg4]vancomycin aglycon, [Ψ[C([dbnd]NH)NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 134:2 (2012), 1284–1297, 10.1021/ja209937s.
245. [245] Xu, J.Q., Murphy, S.L., Kochanek, K.D., Bastian, B.A., Deaths: final data for 2013. Natl. Vital Stat. Rep. 64:2 (2016), 1–119.
246. [246] Yates, J., Schaible, P., Virginiamycin as an antibiotic for poultry feeds. Nature 194 (1962), 183–184.
247. [247] Zhanel, G.G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P.R., Rubinstein, E., Gin, A.S., Hoban, D.J., Karlowsky, J.A., New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:7 (2010), 859–886, 10.2165/11534440-000000000-00000.
248. [248] Pournaras, S., Koumaki, V., Spanakis, N., Gennimata, V., Tsakris, A., Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. Int. J. Antimicrob. Agents 48:1 (2016), 11–18, 10.1016/j.ijantimicag.2016.04.017.
249. [249] Evans, M.E., Feola, D.J., Rapp, R.P., Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:9 (1999), 960–967.
250. [250] WHO, Guidelines of the Programmatic Management of Drug-Resistant Tuberculosis, 2006. Available at: http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf.